Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$1.29B+281.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jesús Antonio Zamora Leon
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 15,254
- Beta
- 0.66
- Country
- LU
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.86
Financials
Revenue
$1.29B+281.6%Net Income
$19.88M+9.2%EBITDA
$145.09M+169.7%Free Cash Flow
$184.03M+2638.9%EPS (diluted)
$0.27-34.1%Shares Outstanding (diluted)
74.24M+68.2%Operating Expenses
$290.13MCash & Debt
$621.57MReturn of Capital
$0.00Revenue by Segment (annual)
$2.92BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.39B | $97.61M | $1.32 |
| 2024 | $4.39B | $110.27M | $1.64 |
| 2023 | $3.88B | $-253.92M | $-5.78 |
| 2022 | $2.45B | $-85.61M | $-1.90 |
| 2021 | $1.92B | $-26.47M | $-0.55 |
| 2020 | $1.44B | $-7.10M | $-0.16 |
| 2019 | $1.38B | $72.69M | $1.69 |
| 2018 | $861.23M | $36.18M | $0.97 |
| 2017 | $722.80M | $22.07M | $0.59 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AUNA's reported EPS growth of 10.6% a year over 8 years.
- EPS in 5 years
- $2.18
- Implied price
- $28.37
- Return from $3.66
- 50.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $14.11 — today's price is already 74.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| 0.6% | 27.3% | 32.5% | 37.0% | 41.0% | 44.6% |
| 5.6% | 33.6% | 39.1% | 43.8% | 48.0% | 51.7% |
| 10.6% | 39.9% | 45.7% | 50.6% | 55.0% | 58.9% |
| 15.6% | 46.3% | 52.3% | 57.4% | 62.0% | 66.1% |
| 20.6% | 52.6% | 58.8% | 64.2% | 69.0% | 73.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
160+128.57%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·4d ago·Positive
Auna S.A. (AUNA) Q3 2026 Earnings Call Transcript Auna S.A. ( AUNA ) Q3 2026 Earnings Call November 18, 2026 8:00 AM EST Company Participants Ana Maria Mora Jesús Zamora Leon - President, CEO & Executive Chairman of the Board Gisele Ferrero - CFO & Executive VP Conference Call Participants Mauricio Cepeda - Morgan Stanley, Research Division Presentation Operator Good morning, and welcome to Auna's Third Quarter 2026 Earnings Conference Call. My name is Alexandra, and I will be the operator for t…
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Auna Q3 Earnings Call Highlights Auna NYSE: AUNA reported 10% foreign-exchange-neutral revenue growth for the third quarter of 2026, but profitability came under pressure from an oncology contract in Colombia and prior-period billing adjustments in Peru, executives said on the company's earnings call.
View source ↗ - Newsmarketbeat.com·30d ago·Neutral
Auna Investor Day: Colombia Pressure Prompts 2026 EBITDA Growth Reset Auna NYSE: AUNA outlined its strategy for expanding an integrated healthcare platform across Latin America at its 2026 Investor Day, while also lowering expectations for adjusted EBITDA growth this year due to reimbursement and contracting pressures in Colombia.
View source ↗ - Newsseekingalpha.com·30d ago·Positive
Auna S.A. (AUNA) Analyst/Investor Day Transcript Auna S.A. (AUNA) Analyst/Investor Day Transcript
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Auna: Improving Hospital Volumes And Attractive Valuation Support A Strong Buy Auna's preliminary Q3 results showed stronger hospital activity across Peru, Colombia, and Mexico, with surgeries up 11.7% year-over-year. Higher hospital occupancy, expansion of oncology services, and contractual price adjustments support our expectations for an EBITDA margin to recover in H2 2026. Auna trades at approximately 4.5x forward EV/EBITDA, below its historical average, while improving FCF could support fur
View source ↗ - Newsmarketbeat.com·95d ago·Neutral
Auna Q2 Earnings Call Highlights Auna NYSE: AUNA reported second-quarter results marked by continued revenue growth, improving cash generation and a sequential recovery in patient volumes in Mexico, though adjusted EBITDA declined amid margin pressures, talent investments and billing-related penalties in Peru.
View source ↗ - Newszacks.com·96d ago·Negative
Auna S.A. (AUNA) Q2 Earnings Miss Estimates Auna S.A. (AUNA) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.33 per share a year ago.
View source ↗ - Newsbusinesswire.com·96d ago·Neutral
Auna Announces 2Q26 Financial Results LUXEMBOURG--(BUSINESS WIRE)--Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today financial results for the second quarter ended June 30, 2026 (“Second quarter 2026” or “2Q26”). Financial results are expressed in Peruvian Soles (“S/” or “PEN” or “Soles”) and are presented in accordance with International Financial Reporting Standards (“IFRS”), unless otherwi…
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $0.23 per share
Typical surprise +33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 17$0.12 vs $0.26miss
- Tue, Aug 18$0.15 vs $0.26miss
- Tue, May 19$0.05 vs $0.19miss
- Tue, Mar 10$0.53 vs $0.13beat
- Thu, Nov 20$0.20 vs $0.15beat
- Tue, Aug 19$0.33 vs $0.13beat
Estimates and results for AUNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AUNA officers and directors.
- Bought
- $357k
- Sold
- $73k
6 trades
1 trade
- Zamora Leon Jesusbought
- Zamora Leon Jesusbought
- Wilton Johnsold
- Zamora Leon Jesusbought
- Zamora Leon Jesusbought
- Zamora Leon Jesusbought
- Zamora Leon Jesusbought
38 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AUNA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
